评估姑息性立体定向放疗(SBRT)在对于不能适用其他局部区域治疗的巴塞罗那临床肝癌分期C(BCLC-C)的肝细胞癌(HCC)患者中的作用。这是一项在2020年5月至2021年9月间进行的回顾性观察性研究。数据源于35例接受SBRT治疗的晚期HCC患者。包括拥有Child Pugh状态（CPs）A5-B7以及肝储备量≥700cc的患者。严格记录局部对比( LC)、总体生存率(OS)以及包括失调在内的不良反应。在样本中，门静脉和下腔静脉的肿瘤栓塞分别出现在33(94.3%)和8(22.85%)的患者中，肺和淋巴结的转移则在11(31.4%)和21(60%)的患者中被发现。中位总肿瘤体积(GTV)为563cc(范围80-1925cc)。SBRT剂量处方的中位数是35 Gy(范围25-40 Gy)，分为5-10次施行。放疗后，24名患者(82.75%)的疼痛和不适得到了改善，23名患者中的18名(78%)疼痛和不适也得到了改善。同时，3名(100%)患者骨转移相关的疼痛也得到了改善。一年的LC和OS分别为80%和30%。多元分析表明，GTV体积>750cc和PIVKA-II>8000 mAU/ml仍是预测不良OS的因素。在SBRT后，7名患者(20%)的Child-Pugh评分变化为1分，并得到了保守治疗。SBRT是BCLC-C HCC的一种安全可行的选择。它不仅通过症状控制改善了生活质量，而且具有良好的LC和OS和可接受的毒性。对于患有晚期HCC的患者，应多学科考虑使用SBRT。©2023. 作者(尚)，在Springer-Verlag GmbH Germany自治区下的独家许可使用。

To evaluate the role of palliative stereotactic body radiation therapy (SBRT) in Barcelona Clinic Liver Cancer stage‑C (BCLC-C) hepatocellular carcinoma (HCC) patients who are not suitable for other loco-regional therapies.It is an observational retrospective study done between May 2020 and September 2021. The data were collected from 35 patients of advanced HCC who underwent SBRT. Patients of Child Pugh status (CPs) A5-B7 and with a liver reserve of ≥ 700cc were included. Local control (LC), overall survival (OS) and adverse events including decompensation were carefully recorded.In the cohort, Portal vein and IVC tumor thrombosis were present in 33 (94.3%) and 8 (22.85%) patients, respectively. Lung and nodal metastasis were found in 11 (31.4%) and 21 (60%) of patients, respectively. The median gross tumor volume (GTV) was 563cc (range 80-1925cc). The median SBRT dose prescription was 35 Gy (range 25-40 Gy) in 5-10 fractions. Post radiation therapy, there was improvement in pain and discomfort in 24 out of 29 (82.75%) and 18 out of 23 (78%) patients respectively. Also bone metastasis related pain was improved in all 3 (100%) patients. One year LC, and OS were 80% and 30% respectively. On multivariate analysis, the GTV volume > 750cc and PIVKA-II > 8000 mAU/ml remained the predictor factor for poor OS. Post SBRT, change in child-pugh score by 1 point was observed in 7 patients (20%) which was managed conservatively.SBRT is a safe and feasible option for BCLC‑C HCC. It not only improves the quality of life by symptom control but also results in good LC and OS with acceptable toxicity. SBRT should be considered in a multidisciplinary fashion for patients presenting with advanced HCCs.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.